top of page
  • Active, not recruiting

NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS

Updated: May 23, 2022


CENTAURUS


CENTAURUS

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.


Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02316106


Official Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

First Posted : December 12, 2014


Click here to see details on ClinicalTrials.gov